Please use this identifier to cite or link to this item:
|Title:||Crosstalk Between Inflammatory Signaling and Methylation in Cancer||Authors:||Das, D
|Issue Date:||24-Nov-2021||Publisher:||Frontiers Media SA||Citation:||Das, D, Karthik, N, Taneja, R (2021-11-24). Crosstalk Between Inflammatory Signaling and Methylation in Cancer. Frontiers in Cell and Developmental Biology 9. ScholarBank@NUS Repository. https://doi.org/10.3389/fcell.2021.756458||Abstract:||Inflammation is an intricate immune response against infection and tissue damage. While the initial immune response is important for preventing tumorigenesis, chronic inflammation is implicated in cancer pathogenesis. It has been linked to various stages of tumor development including transformation, proliferation, angiogenesis, and metastasis. Immune cells, through the production of inflammatory mediators such as cytokines, chemokines, transforming growth factors, and adhesion molecules contribute to the survival, growth, and progression of the tumor in its microenvironment. The aberrant expression and secretion of pro-inflammatory and growth factors by the tumor cells result in the recruitment of immune cells, thus creating a mutual crosstalk. The reciprocal signaling between the tumor cells and the immune cells creates and maintains a successful tumor niche. Many inflammatory factors are regulated by epigenetic mechanisms including DNA methylation and histone modifications. In particular, DNA and histone methylation are crucial forms of transcriptional regulation and aberrant methylation has been associated with deregulated gene expression in oncogenesis. Such deregulations have been reported in both solid tumors and hematological malignancies. With technological advancements to study genome-wide epigenetic landscapes, it is now possible to identify molecular mechanisms underlying altered inflammatory profiles in cancer. In this review, we discuss the role of DNA and histone methylation in regulation of inflammatory pathways in human cancers and review the merits and challenges of targeting inflammatory mediators as well as epigenetic regulators in cancer.||Source Title:||Frontiers in Cell and Developmental Biology||URI:||https://scholarbank.nus.edu.sg/handle/10635/226556||ISSN:||2296634X||DOI:||10.3389/fcell.2021.756458|
|Appears in Collections:||Elements|
Show full item record
Files in This Item:
|Das et al FCDB.pdf||Accepted version||3.97 MB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.